← Leaderboards
Dustin A Deming
University Of Wisconsin-Madison
$5,813,640
Attributed
$6,987,664
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,987,664 · 3
By mechanism
R37$4,217,350 · 1
R01$2,348,049 · 1
P30$422,265 · 1
Top collaborators
- Melissa Caroline Skala5 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Pamela K Kreeger$8,176,069
- David J Beebe$20,083,426
- Ned H Kalin$48,172,395
- Joshua Michael Lang$8,279,603
- Whitney Lee Wharton$4,934,889
Others in their field
Other Emerging Leaders on “Cancer Patient”
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,792,984
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Martha Hering · Westat, Inc.$57,098,843
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
Cancer PatientResponseMalignant NeoplasmsPharmaceutical PreparationsTumorImageMetabolic ImagingMetastatic ColorectalOpticsCellsClinical PredictorsIn VivoMetabolicArchitectureComplexMolecularFluorescenceGeneticColorectal CancerCell CommunicationGenetic HeterogeneityHeterogeneityColon Cancer PatientsIndividual Patient
Grant awards (15)
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$663,363
R01 · FY2025 · CA
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$215,820
R01 · FY2025 · CA
Developmental Therapeutics$140,755
P30 · FY2025 · CA · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$629,799
R01 · FY2024 · CA
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$582,807
R37 · FY2024 · CA · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$156,845
R01 · FY2024 · CA
Developmental Therapeutics$140,755
P30 · FY2024 · CA · contact PI
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids$682,222
R01 · FY2023 · CA
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$601,212
R37 · FY2023 · CA · contact PI
Developmental Therapeutics$140,755
P30 · FY2023 · CA · contact PI
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$606,415
R37 · FY2022 · CA · contact PI
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$606,415
R37 · FY2021 · CA · contact PI
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$611,495
R37 · FY2020 · CA · contact PI
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$593,148
R37 · FY2019 · CA · contact PI
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer$615,858
R37 · FY2018 · CA · contact PI